Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02503501 · ClinicalTrials.gov registry record · Phase 2
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
A Phase 2 study, sponsored by HealthPartners Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT02503501 is a Phase 2 study that was terminated before completion, run by HealthPartners Institute. The registered enrollment target is 49 participants.
The verdict
NCT02503501, a Phase 2 study, was terminated before completion, sponsored by HealthPartners Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
This study evaluates the safety and effectiveness of intranasal (IN) glulisine in patients with amnestic mild cognitive impairment (aMCI) and probable Alzheimer's disease. Half of participants will receive IN glulisine, while the other half will receive IN placebo.
Interventions
- DRUG Placebo
- DRUG Insulin glulisine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2015-09-28 |
| Est. Completion | 2019-02-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02503501
The ClinicalTrials.gov registry entry for NCT02503501 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HealthPartners Institute, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02503501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02503501 about?
NCT02503501 is a clinical study titled "Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease". This study evaluates the safety and effectiveness of intranasal (IN) glulisine in patients with amnestic mild cognitive impairment (aMCI) and probable Alzheimer's disease. Half of participants will receive IN glulisine, while the other half will receive IN placebo.
What is the current status of trial NCT02503501?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2015-09-28. Estimated completion is 2019-02-15.
What interventions are being tested in trial NCT02503501?
The interventions under investigation include: Placebo (DRUG), Insulin glulisine (DRUG).
Who is sponsoring clinical trial NCT02503501?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.